Race enters collaborative preclinical research program with The University of Newcastle to explore use of Bisantrene as a novel FTO directed treatment for melanoma Research designed to identify drug combinations that improve upon current standard of care melanoma treatment with focus on immune checkpoint resistance Project is Race’s first step under Pillar 1 of its Three Pillar strategy, designed to demonstrate Bisantrene’s potential in inhibiting FTO in humans
Ann: Race Initiates FTO Melanoma Preclinical Study, page-5
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |